PROTHENACORP PLC
PROTHENACORP PLC
Aktie · IE00B91XRN20 · PRTA · A1KAVV (XNMS)
Übersicht Finanzkennzahlen
5,11 USD
-2,67 % -0,14 USD
NASDAQ/NMS (GLOBAL MARKET) (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
11.06.2025 21:16

Aktuelle Kurse von PROTHENACORP PLC

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
PRTA
USD
11.06.2025 21:16
5,11 USD
5,26 USD
-2,85 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 2,61 % -31,22 % -62,84 % -63,89 % -75,06 % -48,69 %

Firmenprofil zu PROTHENACORP PLC Aktie

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Investierte Fonds

Folgende Fonds haben in investiert: PROTHENACORP PLC investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
107,09
Anteil (%)
0,25 %

Unternehmensdaten

Name PROTHENACORP PLC
Firma Prothena Corporation plc
Symbol PRTA
Website https://www.prothena.com
Heimatbörse XNMS NASDAQ/NMS (GLOBAL MARKET)
WKN A1KAVV
ISIN IE00B91XRN20
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Gene G. Kinney Ph.D.
Marktkapitalisierung 495 Mio
Land Irland
Währung USD
Mitarbeiter 0,2 T
Adresse 77 Sir John Rogerson’s Quay, 2 Dublin
IPO Datum 2012-12-18

Ticker Symbole

Name Symbol
Frankfurt 0PT.F
NASDAQ PRTA

Weitere Aktien

Investoren die PROTHENACORP PLC die halten, haben auch folgende Aktien im Depot:
ALIGN TECHNOLOGIESLOGY INC
ALIGN TECHNOLOGIESLOGY INC Aktie
AMGEN INC
AMGEN INC Aktie
APPLE INC
APPLE INC Aktie
AUTODESK INC
AUTODESK INC Aktie
CADENCE DESIGN SYSTEMS INC
CADENCE DESIGN SYSTEMS INC Aktie
CISCO SYSTEMS INC
CISCO SYSTEMS INC Aktie
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Aktie
DWS BALANCE
DWS BALANCE Fonds
INTEL CORP
INTEL CORP Aktie
INVESCSDAQ INTERNET ETF
INVESCSDAQ INTERNET ETF ETF
MICROSOFT CORP
MICROSOFT CORP Aktie
POWERCORP OF CDA
POWERCORP OF CDA Aktie
VECTOR GRP LTD
VECTOR GRP LTD Aktie
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025